Skip to main content
Back to Events

AACR 2022 Annual Meeting

Posters & Presentations

  • Evaluation of tissue- and plasma-derived tumor mutational burden and genomic alterations of interest from the CheckMate 848 clinical trial

    Lead Author

    Jonathan Baden

    Collaborator

    Bristol Myers Squibb

    Date | Time

    Monday, April 11 | 2:35 PM - 2:50 PM

    Abstract Number

    2139

    View Abstract
  • TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity

    Lead Author

    Johann S. de Bono

    Collaborator

    Pfizer

    Date | Time

    Monday, April 11 | 3:20 PM - 3:30 PM

    Abstract Number

    CT031

    View Abstract
  • Patients with germline ATM mutations develop clonal hematopoiesis characterized by co-occurrence of multiple somatic ATM alterations

    Lead Author

    Brennan Decker

    Date | Time

    Sunday, April 10 | 1:30 PM – 5:00 PM

    Abstract Number

    57/18

    View Abstract
  • Comprehensive genomic profiling (CGP) reveals site-specific enrichment of immunotherapy biomarkers and targetable alterations in non-small cell lung cancer (NSCLC) metastasis

    Lead Author

    Benjamin G. Kaplan

    Date | Time

    Monday, April 11 | 9:00 AM – 12:30 PM

    Abstract Number

    753/9

    View Abstract
  • Comprehensive genomic profiling of tissue and liquid biopsies reveals the landscape of reversion mutations

    Lead Author

    Shannon T. Bailey

    Date | Time

    Monday, April 11 | 9:00 AM – 12:30 PM

    Abstract Number

    798/7

    View Abstract
  • Leveraging existing data to identify ancestry-associated features across multiple cancer types

    Lead Author

    Jian Carrot-Zhang

    Collaborator

    Dana Farber Cancer Institute

    Date | Time

    Monday, April 11 | 9:00 AM – 12:30 PM

    Abstract Number

    1166/13

    View Abstract
  • Identification of aneuploidy biomarkers associated with response to first-line treatment of metastatic pancreatic cancer

    Lead Author

    Kuei-Ting Chen

    Date | Time

    Monday, April 11 | 9:00 AM – 12:30 PM

    Abstract Number

    1243/15

    View Abstract
  • Development of a pan-cancer algorithm to predict homologous recombination deficiency and sensitivity to PARPi therapy

    Lead Author

    Emmanuel Antonarakis

    Collaborator

    University of Minnesota

    Date | Time

    Monday, April 11 | 9:00 AM – 12:30 PM

    Abstract Number

    1249/21

    View Abstract
  • Clinical utility of circulating tumor DNA sequencing with a large panel: The experience of Gustave Roussy/ National Center for Precision Medicine (PRISM)

    Lead Author

    Arnaud Bayle

    Collaborator

    Gustave Roussy Cancer Center

    Date | Time

    Tuesday, April 12 | 1:30 PM – 5:00 PM

    Abstract Number

    3413/19

    View Abstract